Literature DB >> 34766304

Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.

Eric Savier1, Pierre Tuffery2, Heriberto Bruzzoni-Giovanelli3, Angelita Rebollo4.   

Abstract

Methods for isolation of human primary cells is an important tool to be able to test the effect of several drugs for the treatment of diseases. Protocols have been described for the isolation of healthy and tumoral hepatocytes; however, the quality and the amount of the isolated cells is not satisfactory. We describe here protocols for the isolation of healthy and tumoral hepatocytes as well as the use of tumor penetrating and interfering peptides as new therapeutics. Peptides are showed to be safe drugs and taking into account recent improvements in peptide administration, biodelivery, and bioavailability. Tumor penetrating peptides fused to an interfering peptide have a great potential to become therapeutic agents.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Interfering peptides; Liver cancer; Tumor penetrating peptides

Mesh:

Substances:

Year:  2022        PMID: 34766304     DOI: 10.1007/978-1-0716-1752-6_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  49 in total

1.  Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')2 and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma.

Authors:  Cheng Jin; Ling Bai; Lemin Lin; Shuangquan Wang; Xiaolong Yin
Journal:  Artif Cells Nanomed Biotechnol       Date:  2017-08-04       Impact factor: 5.678

2.  Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma.

Authors:  Sarah Beseme Nambotin; Lydie Lefrancois; Xavier Sainsily; Pascale Berthillon; Miran Kim; Jack R Wands; Michele Chevallier; Pierre Jalinot; Jean-Yves Scoazec; Christian Trepo; Fabien Zoulim; Philippe Merle
Journal:  J Hepatol       Date:  2010-09-16       Impact factor: 25.083

3.  Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.

Authors:  Xiaoyun Wang; Fengbo Wu; Guoyou Li; Nan Zhang; Xiangrong Song; Yu Zheng; Changyang Gong; Bo Han; Gu He
Journal:  Acta Biomater       Date:  2018-05-19       Impact factor: 8.947

Review 4.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.

Authors:  Xin-Yuan Lu; Tao Xi; Wan-Yee Lau; Hui Dong; Zhen Zhu; Feng Shen; Meng-Chao Wu; Wen-Ming Cong
Journal:  Ann Surg Oncol       Date:  2011-02-10       Impact factor: 5.344

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.

Authors:  Ying Zan; Zhijun Dai; Liang Liang; Yujiao Deng; Lei Dong
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

9.  Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.

Authors:  Ying Liu; Xin Wu; Yuan Gao; Jigang Zhang; Dandan Zhang; Shengying Gu; Guanhua Zhu; Gaolin Liu; Xiaoyu Li
Journal:  Int J Nanomedicine       Date:  2016-08-12

10.  Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.

Authors:  Hongyun Zhao; Meng Wu; Leilei Zhu; Yi Tian; Mingxing Wu; Yizhen Li; Liming Deng; Wei Jiang; Wei Shen; Zhigang Wang; Zhechuan Mei; Pan Li; Haitao Ran; Zhiyi Zhou; Jianli Ren
Journal:  Theranostics       Date:  2018-02-14       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.